紫杉醇联合顺铂同步放化疗治疗术后食管癌52例  

Concurrent Radiotherapy and Chemotherapy with Cisplatin plus Paclitaxel for 52 Cases with Esophageal Cancer Postoperation

作　　者：邓霞[1] 吴式琇[1] 孙成超[1] 谢聪颖[1] 张萍[1] 

机构地区：[1]温州医学院附属第一医院,浙江温州325000

出　　处：《肿瘤学杂志》2009年第7期641-644,共4页Journal of Chinese Oncology

摘　　要：[目的]探讨紫杉醇联合顺铂同步放化疗治疗术后食管癌的临床疗效。[方法]2000年10月～2007年10月,52例根治术后的Ⅱ～Ⅲ期食管癌患者均接受紫杉醇联合顺铂化疗同步放疗,放疗剂量:50Gy/25F,5周。[结果]28例(54%)患者发生了Ⅲ/Ⅳ级放化疗毒副反应,主要为白细胞下降/中性粒细胞减少、血小板减少和放射性食管炎。中位生存时间为37.2个月,1、3年生存率分别为82.19%、47.13%。2年局控率、无远处转移生存率和无进展生存率分别为60.01%、71.38%和42.01%。[结论]同步放化疗治疗Ⅱ～Ⅲ期术后食管癌患者可行,毒副反应可耐受。[Purpose] To investigate the clinical value of concurrent radiotherapy and chemotherapy with cisplatin plus paclitaxel for 52 cases with esophageal cancer postoperation. [Methodsl From October 2000 to October 2007, 52 cases with stage Ⅱ～Ⅲ esophageal carcinoma undergoing radical operation received concurrent radiotherapy（50Gy/25F,5 weeks） and chemotherapy with cisplatin plus paclitaxel. [Resultsl Twenty-eight cases （54%） experienced grade Ⅲ/Ⅳ toxicity mostly leukopenia/neutropenia, thrombocytopenia and radiation esophagitis. The median survival was 37.2 months, 1-year and 3-year survival were 82.19% and 47.13% respectively. The 2-year local-regional control survival, distant metastasis free survival and progression-free survival were 60.01%, 71.38% and 42.01% respectively. [Conclusion] Concurrent radiotherapy and chemotherapy with cisplatin plus paelitaxel for postoperative esophageal cancer is feasible and tolerable.

关 键 词：食管肿瘤 放射疗法 药物疗法 术后治疗 

分 类 号：R735.1[医药卫生—肿瘤]